Experts gathered at the TCT MedTech Innovation Forum to discuss successes, failures, barriers, and solutions in healthcare.

HF outcomes at 3 years were improved, but where stem cells fit in future research is the big unknown, says Jay Traverse.

A total of 399 patients underwent TEE and were taking their assigned treatment at 60 days follow-up.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...

One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.

Changes are afoot to meet higher caseloads amid rising demand, the survey of 6,830 cardiovascular providers suggests.

It’s the height of meeting season! All our most-read stories this month hailed from the news team’s on-site coverage.

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.

The national coverage determination explicitly outlines patient, clinician, and facilities criteria for qualifying procedures ...

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...